🇺🇸 Daratumumab Hyaluronidase-fihj in United States

417 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Neutrophil Count Decreased — 51 reports (12.23%)
  2. Pneumonia — 49 reports (11.75%)
  3. Dyspnoea — 48 reports (11.51%)
  4. Therapy Interrupted — 44 reports (10.55%)
  5. Pyrexia — 40 reports (9.59%)
  6. Neutropenia — 39 reports (9.35%)
  7. Fatigue — 38 reports (9.11%)
  8. Off Label Use — 38 reports (9.11%)
  9. Sepsis — 36 reports (8.63%)
  10. Plasma Cell Myeloma — 34 reports (8.15%)

Source database →

Other Oncology approved in United States

Frequently asked questions

Is Daratumumab Hyaluronidase-fihj approved in United States?

Daratumumab Hyaluronidase-fihj does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Daratumumab Hyaluronidase-fihj in United States?

Memorial Sloan Kettering Cancer Center is the originator. The local marketing authorisation holder may differ — check the official source linked above.